According to a recent study published in the Journal of Urology, men with localized prostate cancer on hormone therapy (ADT) have a significant increase in their risk for developing diabetes. In this retrospective study of 12,191 men with localized prostate cancer who did not have diabetes were followed once they went on ADT. It was [...]
JAMA Oncology has published a new study that suggests that adding a statin drug at the initiation of hormone therapy (ADT) to the treatment protocol for a man with progressive, hormone-sensitive prostate cancer may significantly impact their actual time to disease progression (TTP). Historically, we know Statin use has been associated with improved prostate cancer [...]
Men who develop bone metastases have often been viewed as having developed a significant negative change that prognosticates a negative impact on both their quality of life and on their survival. Contradicting this commonly held belief has been some research which has identified a subgroup of men with advanced prostate cancer with bone metastases who [...]
Starting androgen deprivation therapy (ADT) to treat advanced prostate cancer is usually the start of a long treatment period that will continue for many years, actually until you die. Since our goal in cancer treatment is to make cancer a chronic illness and since prostate cancer does progress for most men in a relatively slow [...]
A recently previewed (prior to the upcoming ASCO Annual Meeting) of a large study shows that men with prostate cancer who had a PSA-based relapse (Biochemical Recurrence) could delay starting androgen deprivation therapy (ADT) until they started experiencing symptoms from the cancer. They found that this delay would not affect the men’s long-term survival. The [...]